01—Abstract
Summary
Summary of the 8-K filed February 22, 2024. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. (MRNA) has filed an 8-K report on February 22, 2024, primarily to furnish its fourth quarter and full-year 2023 financial results as announced via press release.
The key takeaway for investors is that the company has provided an update on its financial performance, although the detailed financial figures are contained within the furnished press release (Exhibit 99.1) and not directly enumerated within the 8-K's text itself. Investors should refer to the press release for specific revenue, profit, and cash flow details for the periods ending December 31, 2023.
This filing serves as the official record of the press release's dissemination, assuring investors that the information presented by Moderna regarding its financial condition and operational results has been formally communicated. While the 8-K itself is a brief document, it directs stakeholders to the comprehensive unaudited financial results and management's discussion and analysis provided in the press release, which is crucial for evaluating Moderna's current financial health and future prospects.
02—Key points
Key Highlights
- Moderna announced its Q4 and full-year 2023 financial results on February 22, 2024, via a press release.
- The 8-K filing incorporates this press release (Exhibit 99.1) by reference, providing investors access to the detailed financial performance data.
- This filing is primarily informational, confirming the release of the company's financial results for the specified periods.
- Investors are directed to the furnished press release for specific financial metrics, including revenue, earnings, and operational highlights.
- The information furnished is not deemed 'filed' for purposes of Section 18 of the Exchange Act, but is incorporated by reference into specific filings where explicitly noted.
- The filing also includes the Cover Page Interactive Data File in Inline XBRL format.
03—Questions
Frequently Asked Questions
What is the main purpose of this 8-K filing?
The main purpose of this 8-K filing is to formally report and provide investors with access to Moderna's financial results for the fourth quarter and full year ended December 31, 2023, which were announced via a press release.
Where can I find the specific financial details (revenue, profit, etc.)?
The specific financial details are contained within the press release issued by Moderna on February 22, 2024, which is furnished as Exhibit 99.1 to this 8-K filing and incorporated by reference. Investors should refer to that document for comprehensive financial data.
Is the information in this 8-K 'filed' with the SEC, or just 'furnished'?
The information in this Current Report on Form 8-K, including the press release, is intended to be 'furnished' and shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, nor subject to its liabilities, unless expressly incorporated by reference in another filing.
What are the key financial figures reported?
This 8-K filing itself does not enumerate the specific financial figures. Investors must consult the furnished press release (Exhibit 99.1) for details on revenue, net income/loss, earnings per share, cash flow, and other performance metrics for Q4 and the full year 2023.
04—Continue